Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Thymus Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 5Cisplatin 5pembrolizumab 4Cyclophosphamide 4Thymectomy 3Sunitinib 3130-nm albumin-bound paclitaxel 3selinexor 2Pemetrexed 2Methylprednisolone 2Etoposide 2Drug Therapy 2Doxorubicin 2Chemoradiotherapy 2Carboplatin 2zimberelimab 1vorolanib 1regorafenib 1lenvatinib 1epacadostat 1envafolimab 1bosutinib 1amrubicin 1Thoracic Surgery, Video-Assisted 1TP protocol 1Ramucirumab 1Radiotherapy, Adjuvant 1Radiosurgery 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thymoma × amrubicin × Clear all
NCT01364727 2019-04-16

A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies

Stanford University

Phase 2 Completed
33 enrolled 11 charts
Thoracic

Thymoma, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡